Lihua Li

Lihua Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2022 in Neuropharmacology
Verified
Journal Article
Closed access
GYGenmeng Yang
Genmeng Yang
JLJuan Li
Juan Li
CLChi-Kwan Leung
Chi-Kwan Leung
BSBaoyu Shen
Baoyu Shen
CWChan Wang
Chan Wang
LLLihua Li
Lihua Li

2 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XCXi Chen
Xi Chen
SPShanrui Pu
Shanrui Pu
KLKun Lian
Kun Lian
LLLihua Li
Lihua Li
XJXiulin Jiang
Xiulin Jiang
N6-methyladenosine (m6A) is the most prevalent internal modification of eukaryotic mRNA and has emerged as a pivotal regulator of gene expression at the post-transcriptional level. In the tumor immune microenvironment, tumor-associated macrophages (TAMs) represent a highly plastic and heterogeneous population that profoundly influences cancer progression, immune evasion, and therapeutic response. Recent studies have uncovered that m6A modification, mediated by dynamic “writers,” “erasers,” and “readers,” exerts critical regulatory effects on TAM differentiation, polarization, and functional reprogramming. By modulating the stability, translation, and decay of transcripts involved in inflammatory signaling, metabolic adaptation, and immune checkpoints, m6A shapes the balance between tumor-promoting (M2-like) and tumor-suppressive (M1-like) macrophage phenotypes. Moreover, dysregulation of m6A machinery in TAMs has been linked to the suppression of anti-tumor immunity and resistance to immunotherapy, highlighting its translational potential as a therapeutic target. This review summarizes current advances in understanding the roles and mechanisms of m6A modification in TAM biology, discusses its implications in tumor immunity, and outlines the challenges and opportunities of targeting the m6A–TAM axis for cancer treatment.

8 January 2022 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
BSBaoyu Shen
Baoyu Shen
DZDongxian Zhang
Dongxian Zhang
XZXiaofeng Zeng
Xiaofeng Zeng
LGLina Guan
Lina Guan
GYGenmeng Yang
Genmeng Yang
LLLihua Li
Lihua Li

9 August 2023 in Toxicology Letters
Verified
Journal Article
Closed access
WDWenjuan Dong
Wenjuan Dong
JWJia Wan
Jia Wan
HYHao Yu
Hao Yu
BSBaoyu Shen
Baoyu Shen
GYGenmeng Yang
Genmeng Yang
SHShijun Hong
Shijun Hong

6 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
BSBaoyu Shen
Baoyu Shen
RZRuilin Zhang
Ruilin Zhang
GYGenmeng Yang
Genmeng Yang
YPYanxia Peng
Yanxia Peng
QNQianyun Nie
Qianyun Nie
LLLihua Li
Lihua Li
In the past decade, methamphetamine (METH) abuse has sharply increased in the United States, East Asia, and Southeast Asia. METH abuse not only leads to serious drug dependence, but also produces irreversible neurotoxicity. Currently, there are no approved pharmacotherapies for the treatment of METH use disorders. Cannabidiol (CBD), a major non-psychoactive (and non-addictive) cannabinoid from the cannabis plant, shows neuroprotective, antioxidative, and anti-inflammatory properties under METH exposure. At present, however, the mechanisms underlying these properties remain unclear, which continues to hinder research on its therapeutic potential. In the current study, computational simulations showed that CBD and METH may directly bind to the dopamine receptor D1 (DRD1) via two overlapping binding sites. Moreover, CBD may compete with METH for the PHE-313 binding site. We also found that METH robustly induced apoptosis with activation of the caspase-8/caspase-3 cascade in-vitro and in-vivo, while CBD pretreatment prevented these changes. Furthermore, METH increased the expression of DRD1, phosphorylation of Methyl-CpG-binding protein 2 (MeCP2) at serine 421 (Ser421), and level of intracellular Ca2+in-vitro and in-vivo, but these effects were blocked by CBD pretreatment. The DRD1 antagonist SCH23390 significantly prevented METH-induced apoptosis, MeCP2 phosphorylation, and Ca2+ overload in-vitro. In contrast, the DRD1 agonist SKF81297 markedly increased apoptosis, MeCP2 phosphorylation, and Ca2+ overload, which were blocked by CBD pretreatment in-vitro. These results indicate that CBD prevents METH-induced neurotoxicity by modulating DRD1-mediated phosphorylation of MeCP2 and Ca2+ signaling. This study suggests that CBD pretreatment may resist the effects of METH on DRD1 by competitive binding.

23 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
XJXiulin Jiang
Xiulin Jiang
YSYulin Shi
Yulin Shi
XCXi Chen
Xi Chen
HXHaitao Xu
Haitao Xu
BLBohu Liu
Bohu Liu
JPJun Pu
Jun Pu
Background: Non-SMC condensin I complex subunit G (NCAPG) is expressed in various human cancers, including gliomas. However, its biological function in glioma remains unclear. The present study was designed to determine the biological functions of NCAPG in glioma and to evaluate the association of NCAPG expression with glioma progression.Methods: Clinical data on patients with glioma were obtained from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), the Gene Expression Omnibus (GEO), and the Rembrandt and Gravendeel databases. The correlations among NCAPG expression, pathological characteristics, and clinical outcome were evaluated. In addition, the correlations of NCAPG expression with immune cell infiltration and glioma progression were analyzed.Results: NCAPG expression was higher in gliomas than in adjacent normal tissues. Higher expression of NCAPG in gliomas correlated with poorer prognosis, unfavorable histological features, absence of mutations in the isocitrate dehydrogenase gene (IDH), absence of chromosome 1p and 19q deletions, and responses to chemoradiotherapy. Univariate and multivariate Cox analysis demonstrated, in addition to patient age, tumor grade, absence of IDH mutations, and absence of chromosome 1p and 19q deletions, NCAPG expression was independently prognostic of overall survival, disease-free survival, and progression-free survival in patients with glioma. In addition, high expression of NCAPG correlated with tumor infiltration of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells. Gene set enrichment analysis (GSEA) indicated that high NCAPG expression was associated with cell proliferation and immune response-related signaling pathways. NCAPG knockdown in glioma cell lines significantly reduced cell survival, proliferation, and migration.Conclusion: NCAPG expression correlates with glioma progression and immune cell infiltration, suggesting that NCAPG expression may be a useful prognostic biomarker for glioma.